Saudi practical guidelines on biologic treatment of psoriasis

Hamadah, Issam; Raddadi, Ali; Bahamdan, Khalid; Fatani, Mohammad I.; Alnahdi, Ali; Rakban, Abdullah M Al; Alkhalifah, Abdullah; Ameer, Ali Al; Shaikh, Yasir; Elgendi, Ayman M; Zoman, Abdulrahman Y Al; Al-Afif, Khalid A.

doi:10.3109/09546634.2014.946882

Cited by 17 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search returned a total of 145 publications and 10 of these described patients in Africa or the Middle East. Of these 10 publications, there were 4 research articles ( Table 1 ), 20 – 23 3 reviews ( Table 2 ), 8 , 24 , 25 2 guidelines (1 from South Africa in 2010 and 1 from Saudi Arabia in 2014; Table 3 ), 26 , 27 and 1 case study (published in Hebrew). 28 Two of the 4 research articles described non-interventional studies and 2 reported data from studies on the safety and efficacy of phototherapy (1 in patients with plaque psoriasis localized to the scalp or palmoplantar areas and 1 in patients ≥65 years of age).…”

Section: Resultsmentioning

confidence: 99%

<p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>

Steinhoff¹,

Ammoury²,

Ahmed³

et al. 2020

PTT

View full text Add to dashboard Cite

Purpose: Dermatologists practicing in African and Middle Eastern countries face numerous challenges when managing patients with plaque psoriasis, especially those with disease in a difficult-to-treat anatomic area or those who are a pediatric, geriatric, or pregnant patient. The publication of comprehensive, up-to-date, region-specific clinical guidelines may help to address some of these challenges and improve outcomes. We conducted a literature review to identify recent guidelines and other publications describing patients with plaque psoriasis in Africa and the Middle East. Patients and Methods: An online literature search of the PubMed database was conducted to identify publications reporting clinical guidelines and research studies on plaque psoriasis. The search included all articles published from January 2008 to March 2020 inclusive. The titles and abstracts of all search results were screened by a reader to identify those that described patients in Africa or the Middle East. Results: A total of 145 publications were identified by the literature search and screened by a reader. There were 10 publications that described patients in Africa or the Middle East: 4 research articles, 3 reviews, 2 guidelines, and 1 case study. The 2010 guidelines from South Africa made recommendations for treating plaque psoriasis of varying severity, although without specific recommendations for difficult-to-treat anatomic areas or pediatric, geriatric, or pregnant patients. The 2014 guideline on biologics from Saudi Arabia included recommendations for the use of these agents in patients with plaque psoriasis, including difficult-to-treat anatomic areas and pediatric patients (TNF inhibitors only), but provided no recommendations for pregnant or geriatric patients. Conclusion: There is an urgent unmet need for comprehensive clinical guidelines on the management of patients with plaque psoriasis in Africa and the Middle East. Region-specific studies on the epidemiology, burden of disease, and the safety and effectiveness of newer pharmacotherapies are needed to support the development of such guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

<p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>

Steinhoff¹,

Ammoury²,

Ahmed³

et al. 2020

PTT

View full text Add to dashboard Cite

show abstract

“…Until now, DR has mainly been described for TNFα inhibitors and ustekinumab [ 10 – 13 ]. The possibility of DR is only mentioned in a few guidelines [ 44 , 45 ]. To our knowledge, the current study is the first randomized, controlled trial designed to investigate disease activity-guided DR of IL-17i and IL-23i for psoriasis patients with low disease activity in a multicentric and pragmatic setting.…”

Section: Discussionmentioning

confidence: 99%

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Schoot

Reek

Grine

et al. 2021

Trials

View full text Add to dashboard Cite

Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis factor (TNF)-alfa inhibitors and ustekinumab could successfully lower their dose, after following a tightly controlled DR strategy. The objective of this study is to assess whether controlled DR of interleukin (IL)-17 and IL-23 inhibitors in psoriasis patients with low disease activity is non-inferior (NI) to usual care (UC). Methods This is an international, prospective, multicenter, pragmatic, randomized, non-inferiority trial. A total of 244 patients with stable low disease activity (Psoriasis Area and Severity Index (PASI) ≤ 5) for at least 6 months and using secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, or tildrakizumab in the standard dose, together with stable low disease activity, defined as a PASI ≤ 5 and Dermatology Life Quality Index (DLQI) ≤ 5 at the moment of inclusion, will be randomized 2:1 to DR or UC. In the DR group, dosing intervals will be prolonged stepwise to achieve 66% and 50% of the original dose. Disease activity is monitored every 3 months by PASI and DLQI. In case of disease flare (i.e., PASI and/or DLQI increase), treatment is adjusted to the previous effective dose. The primary outcome is the incidence proportion of persistent flares (PASI > 5 for ≥ 3 months), which will be compared between arms. Secondary outcomes include proportion of patients with successful DR, (course of) PASI and DLQI, serious adverse events (SAEs), health-related quality of life, costs, and pharmacokinetic profile. Outcomes of DR will be compared to UC. Discussion With this study, we aim to assess whether DR of IL-17 and IL-23 inhibiting biologics can be achieved for psoriasis patients with low disease activity, without losing disease control. Reducing the dose may lead to more efficient use of biologics. Trial registration ClinicalTrials.govNCT04340076. Registered on April 9 2020.

show abstract

“…Research on the quality of life of psoriasis patients has also been the concern of some previous researchers, including research on the quality of life of psoriasis patients in the Osmanabad region, India. The results showed that the quality of life was low and very disturbing in life compared to other healthy individuals [10]. Another study examined the quality of life in patients with psoriasis in tertiary care hospitals concluded that psoriasis is a chronic recurrent disease and has a significant negative impact to the quality of life of the patient [11].…”

Section: Based On Medical Record Data Of Haji Adam Malik General Hospmentioning

confidence: 99%

Improving the Quality of Life in Psoriasis Patient Through Health Promotion Approach at Haji Adam Malik General Hospital, Medan, Indonesia

Meher

Roesyanto

Rochadi

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Psoriasis is a chronic inflammatory skin disease, can affect all ages characterized by reddish plaques that are covered by thick scales of silvery white and firmly bounded. Psoriasis is a skin disease that is difficult to cure because psoriasis can interfere with life quality of life behavior even cause the level of stress for the patient. This study aims to evaluate the effect of health promotion of quality of life of psoriasis patients.Methods: This research is an experiment between pre- and post-test that aims to know the effort of improving the quality of life of psoriasis patient through a health promotion approach. Population in this research is patient of psoriasis in the draft of human rights number 60 people. Then, divide the questioner to the respondents who made twice before the health promotion and after health promotion in the experimental group.Result: The study showed significant differences between pre- and post-test values for quality of life, stress level, and behavior toward health promotion. Data analysis with paired t-test at 95% confidence level, quality of life with lecture method (p=0.001), quality of life (p=0.001), and behavior with method of Booklet (p=0.001).Conclusion: It is recommended for health workers more often to provide health promotion because psoriasis is chronic and recidive disease, it is necessary to improve the quality of service in hospitals by providing education in the form of health promotion in patients not to quickly despair and can comply with doctor’s advice.

show abstract

Saudi practical guidelines on biologic treatment of psoriasis

Cited by 17 publications

References 45 publications

<p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>

<p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Improving the Quality of Life in Psoriasis Patient Through Health Promotion Approach at Haji Adam Malik General Hospital, Medan, Indonesia

Contact Info

Product

Resources

About